The choice of mammalian cell host and possibilities for glycosylation engineering.
about
Advancement of Sialyltransferase Inhibitors: Therapeutic Challenges and OpportunitiesA systematic study of glycopeptide esterification for the semi-quantitative determination of sialylation in antibodies.Mass spectrometric analysis of products of metabolic glycan engineering with azido-modification of sialic acids.Effect of Temperature Downshift on the Transcriptomic Responses of Chinese Hamster Ovary Cells Using Recombinant Human Tissue Plasminogen Activator Production Culture.A Designed Angiopoietin-1 Variant, Dimeric CMP-Ang1 Activates Tie2 and Stimulates Angiogenesis and Vascular Stabilization in N-glycan Dependent Manner.Modification of Asparagine-Linked Glycan Density for the Design of Hepatitis B Virus Virus-Like Particles with Enhanced Immunogenicity.Human cell lines for biopharmaceutical manufacturing: history, status, and future perspectives.Quantitative intracellular flux modeling and applications in biotherapeutic development and production using CHO cell cultures.HEK293T cell lines defective for O-linked glycosylation.Glycosylation profile and biological activity of Remicade® compared with Flixabi® and Remsima®.New Mammalian Expression Systems.Modulation and modeling of monoclonal antibody N-linked glycosylation in mammalian cell perfusion reactors.Benchmarking of commercially available CHO cell culture media for antibody production.Impact of cell culture on recombinant monoclonal antibody product heterogeneity.Production of recombinant coagulation factors: Are humans the best host cells?Glycoengineering of CHO Cells to Improve Product Quality.Opportunities for therapeutic antibodies directed at G-protein-coupled receptors.Low glucose depletes glycan precursors, reduces site occupancy and galactosylation of a monoclonal antibody in CHO cell culture.A Markov chain model for N-linked protein glycosylation--towards a low-parameter tool for model-driven glycoengineering.Physicochemical and biological characterization of SB2, a biosimilar of Remicade® (infliximab).Methods for Using Small Non-Coding RNAs to Improve Recombinant Protein Expression in Mammalian Cells.Impact of host cell line choice on glycan profile.Solid-Phase Enzymatic Remodeling Produces High Yields of Single Glycoform Antibodies.Identifying HIPK1 as Target of miR-22-3p Enhancing Recombinant Protein Production From HEK 293 Cell by Using Microarray and HTP siRNA Screen.Recombinant Proteins and Monoclonal Antibodies.Site-specific glycosylation profile of influenza A (H1N1) hemagglutinin through tandem mass spectrometry.Platforms for Recombinant Therapeutic Glycoprotein Production.Identification of a potent MAR element from the human genome and assessment of its activity in stably transfected CHO cells.Implementation of Glycan Remodeling to Plant-Made Therapeutic Antibodies.Human thyroid-stimulating hormone synthesis in human embryonic kidney cells and related N-glycoprofiling analysis for carbohydrate composition determination.Functional implications of corticosteroid-binding globulin N-glycosylation.Knocking out Ornithine Decarboxylase Antizyme 1 (OAZ1) Improves Recombinant Protein Expression in the HEK293 Cell Line.Bunyaviruses: from transmission by arthropods to virus entry into the mammalian host first-target cellsImproving Immunotherapy Through Glycodesign
P2860
Q30039640-51CB4C06-FB05-45AE-9B75-D96C09AB2BCFQ35762130-705DD9ED-301A-4D38-845C-8B44C51978B4Q35771248-EF57A929-F63D-4A42-953E-B2A618FFC931Q35962616-C10B819E-5A4D-4BE3-A84D-63AD378A74FDQ36174711-6DC7735A-71E5-4579-B73C-767ED9390705Q36281860-0F430201-9A43-4757-A427-AE00BDBF11CBQ37494846-6C6C3C02-FEF6-4F2F-BE2B-1A0417FC6910Q38697277-F6635945-80A6-4E9B-90C2-F095221740E3Q38698865-8DB8C117-E698-4937-A1CC-26BB19C91747Q38699354-2ABBEDA7-BA7B-4322-AAD5-D565E25033ACQ38701179-40DD21A4-70ED-42CB-865F-ABA3DC596D42Q38836971-60BCD4ED-FBD1-4195-8A14-B17E0DB8A75EQ38890492-AEFB5B11-8E89-4DBC-B9BE-ACD9784148F5Q38907094-B549261B-6BB7-4020-85B1-ABC9FFF80C9DQ39170433-A2C0C263-75A7-462E-8BE0-B24635E93693Q39298073-FCBAD028-A705-4173-A42E-640AB6BE145DQ39433833-5FD12798-82C8-4C03-A9D8-09CCEEFF9A55Q40853167-4358C70F-B3D7-4E9C-952C-27B4D6036AF1Q41144980-F06CA90A-D1F0-410F-9626-C1F7088AC7E3Q42113781-2594CB71-940B-453D-9B22-738194729641Q47190209-067A31E8-E621-40DE-BA27-6B99F3807708Q47269842-D238AC7C-BE74-444B-A0C7-E1D134CDFF1BQ47286747-F19261B3-09B2-46EC-8A6D-07E9FEEDB06DQ47592940-5B576CF1-111B-45B4-A9F2-0952A12C062DQ47602370-D19E397E-AADB-4111-94DF-60FB35307705Q47607365-26226FA5-A43B-4EAC-846C-984BE6E9C11AQ47786965-AE2645DA-7A8C-4B60-B7E3-376DA20690D2Q48114473-EF3E5BCB-4509-4E8E-A1CA-49624463DFC0Q48134110-E60305ED-A0A3-4667-8D6A-107BE94F2401Q48567414-7843D973-FC01-4B06-83D6-266BB5454970Q49606754-32076385-2372-4674-A1C7-45C737C7A00BQ55416316-7584D3D3-1AE8-4310-BFE4-BEE69E87597AQ56881173-8F5BFECC-7965-4AA2-B3AD-E105EF506156Q59132146-38259756-3B91-4241-A0DD-D83C62A92F75
P2860
The choice of mammalian cell host and possibilities for glycosylation engineering.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
The choice of mammalian cell host and possibilities for glycosylation engineering.
@en
type
label
The choice of mammalian cell host and possibilities for glycosylation engineering.
@en
prefLabel
The choice of mammalian cell host and possibilities for glycosylation engineering.
@en
P1476
The choice of mammalian cell host and possibilities for glycosylation engineering
@en
P2093
Maureen Spearman
P304
P356
10.1016/J.COPBIO.2014.06.010
P577
2014-07-05T00:00:00Z